SCHEMBL5407610

SCHEMBL5407610

NC(=O)c1ccc(C(F)(F)F)cc1C(F)(F)F.O=S(=O)(O)/C=C/c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES2 O00748 2/20 0.47
AVPR2 P30518 1/20 0.43
GPR27 Q9NS67 1/20 0.43
MAOB P27338 2/20 0.41
CYP1A1 P04798 1/20 0.41
CYP1B1 Q16678 1/20 0.41
FLT1 P17948 1/20 0.40
FLT4 P35916 1/20 0.40
KDR P35968 1/20 0.40
KDM4E B2RXH2 2/20 0.39
ALDH1A1 P00352 2/20 0.39
HSD17B10 Q99714 2/20 0.39
GPR52 Q9Y2T5 1/20 0.39
HPGD P15428 1/20 0.39
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA7 P43166 1/20 0.38
CA9 Q16790 1/20 0.38
PTGES2 Q9H7Z7 2/20 0.38
GRIN1 Q05586 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5408837 0.89 FLT1 (0.44) CES2FLT1FLT4KDRGPR52
SCHEMBL5403847 0.88 KDR (0.51) CES2AVPR2GPR27MAOBFLT1
SCHEMBL4620011 0.88 HTR2A (0.41) MAOBKDM4EALDH1A1HSD17B10PTGES2
SCHEMBL27717789 0.88 HTR2A (0.41) MAOBKDM4EALDH1A1HSD17B10PTGES2
SCHEMBL5411196 0.87 GRIK1 (0.40) MAOBFLT1FLT4KDRKDM4E
SCHEMBL27717857 0.87 GRIK1 (0.40) MAOBFLT1FLT4KDRKDM4E
SCHEMBL5414306 0.87 NFE2L2 (0.42) CYP1B1KDM4EALDH1A1HSD17B10GPR52
SCHEMBL27738991 0.87 NFE2L2 (0.42) CYP1B1KDM4EALDH1A1HSD17B10GPR52
SCHEMBL4261210 0.87 NAMPT (0.45) CES2PTGS2
SCHEMBL5411908 0.85 MAOB (0.43) CES2MAOBKDM4EALDH1A1GPR52

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US claimed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US claimed
US-7208526-B2 For example, (E)-2-(4-Chloro-phenyl)-ethenesulfonic acid 2,4-dichloro-benzoylamide; for use in the control or prevention of illnesses such as cancer; antitumor agents HOFFMANN-LA ROCHE INC. (US) 2007-04-24 US disclosed
US-20060270874-A1 Styrylsulfonamides HOFFMANN-LA ROCHE INC. 2006-11-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060270874-A1 Styrylsulfonamides STS, SULT1E1, BRCA1 CES2 50/4885AVPR2 1465/4885GPR27 2825/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.